C oordinated endothelial cell (EC) cycle activity is vital for the integrity and reconstitution of the innermost lining of arterial blood vessels in health and disease. The endothelium keeps the underlying smooth muscle cell (SMC) layer in a quiescent state via paracrine signaling and cell-cell interactions and by shielding it from circulating growth factors. Efficient reendothelialization after intimal injury becomes clinically important, for example, after percutaneous arterial angioplasty, bearing the risk of obstructive neointima formation caused by SMC proliferation and migration. 1,2 Although the use of growth-inhibitory drug-eluting stents has significantly reduced the restenosis rate, deciphering the molecular mechanisms that might facilitate or hinder vascular reendothelialization remains clinically relevant in efforts to improve therapeutic approaches.
EF-hand Ca 2+ -binding protein superfamily, including familiar Ca 2+ -buffer and Ca 2+ -sensor proteins, such as parvalbumin and calmodulin, respectively. Mostly acting as molecular decoders and transducers of intracellular Ca 2+ signals via interaction with intracellular target proteins, S100 proteins are key components of the cell's versatile molecular toolkit to translate Ca 2+ signals into specific actions. These extend from Ca 2+ -dependent regulation of muscle contraction, membrane excitability, secretion, motility, signaling, and differentiation, to general features, such as cell cycle activity. 5 Although previous reports highlighted a potential role for S100A6 in modulating p44/42 (extracellular signal-regulated kinase 1/2) and β-catenin signaling, 6 the molecular mechanism by which S100A6 potentially affects cell cycle entry and progression in ECs remains elusive.
Inhibition of cell cycle entry in many cell types depends on a family of latent cytoplasmic transcription factors known as signal transducers and activators of transcription (STAT). Biochemical and molecular analyses have indicated that STAT activity is regulated predominantly by phosphorylation on specific tyrosine residues (Tyr-701 in the case of STAT1), which causes STAT dimerization. 7, 8 STAT1 homodimers then translocate into the nucleus and bind to consensus DNA-binding sites that represent enhancer sequences, for example, for a variety of antiproliferative genes. 7, 8 One group of antiproliferative genes that are expressed in response to activated STAT1 encompasses interferon-inducible (IFI) proteins. Specifically, interferon-induced transmembrane protein 1 (IFITM1) is induced by STAT1 signaling, thereby leading to downstream activation of p53/p21 and cell cycle arrest. 9, 10 Great progress has been made in better understanding the regulation of STAT activity. 11 Protein inhibitors of activated STAT 1 to 4 (PIAS 1-4) have been identified to mitigate STAT signaling at different levels. 12 PIAS1, for example, negatively interferes with the DNA-binding activity of STAT1, thereby acting as an inhibitory transcriptional coregulator. 13 Furthermore, PIAS attenuates phosphorylation of STAT1-Tyr-701 and makes tyrosine phosphorylated STAT1 more susceptible to inactivation by nuclear phosphatases (eg, TC45). 14, 15 In addition, suppressors of cytokine signaling (SOCS) exert a negative feedback evoked by nuclear STAT activity. 16 SOCS bind to phosphorylated nonreceptor tyrosine Janus kinases 1 and 2 (JAK1/2) and their receptors to interrupt the transmission between JAK and STAT molecules. 17 A link between the cell cycle regulator S100A6 and the antiproliferative STAT1 cascade and PIAS has not been reported yet.
Originating from the clinically relevant observation of enhanced intimal S100A6 protein expression in remodeling coronary and carotid arteries, we combined time-resolved transcriptome data with bioinformatic analysis to elucidate the molecular pathways through which S100A6 affects EC cycle activation. This unbiased approach led to successful identification and validation of key components of the in silico modeled pathway, and, for the first time, linked S100A6 to antiproliferative STAT1/IFITM1 signaling through the modulation of PIAS activity. Hence, augmented S100A6 expression during vascular remodeling may facilitate reendothelialization by controlling antiproliferative STAT1 signaling. In addition, these novel findings advance our understanding about the role of S100A6 beyond molecular vascular medicine. S100A6/STAT1 signaling may also represent a valuable therapeutic target in oncology given the established role of S100A6 as a biomarker in various cancer types and molecular driver of tumorigenesis. 6, [18] [19] [20] 
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

S100A6 Is Upregulated During Vascular Remodeling After Arterial EC Injury
We found S100A6 protein to be expressed in all layers, and particularly abundant in ECs (the intimal layer), of both porcine coronary and rat carotid arteries ( Figure 1A ; Figure IA through IC in the online-only Data Supplement). When vascular remodeling was induced by intimal injury because of experimental stent implantation or balloon angioplasty, we observed an increase in the immunofluorescence and immunohistochemical S100A6 signal in proliferating vascular cells of both arteries ( Figure 1A ; Figure IA through IC in the online-only Data Supplement). When arterial reendothelialization had occurred, the S100A6 signal returned to baseline and was largely confined to ECs again ( Figure 1A ; Figure IA in the online-only Data Supplement). These observations in clinically relevant in vivo endothelial injury models prompted the investigation of the regulation of S100A6 expression in vitro. Proliferation was induced in quiescent and cell cycle-synchronized cultured human umbilical vein ECs (HUVECs) and vascular SMCs by vascular endothelial growth factor A (VEGF-A) stimulation. VEGF-A exposure led to a 4.7-fold increase in endothelial S100A6 protein expression within 72 hours ( Figure 1B) , which was confirmed by S100A6 immunofluorescence staining ( Figure 1C ). Similar results were observed in human SMCs ( Figure ID in the online-only Data Supplement). In this study, we focused on the biological significance of S100A6 in EC proliferation, given the importance of efficient arterial reendothelialization to mitigate vascular remodeling. S100A6 Is Required for Human EC Cycle Activation and Proliferation S100A6 siRNA knockdown was carried out in HUVECs, which led to a 60% reduction of S100A6 protein levels that persisted with VEGF-A stimulation (Figure 2A ). Control experiments showing unchanged S100A4 and S100B expression in response to S100A6 siRNA treatment confirmed the specificity of our experimental approach (Figure IIA in the online-only Data Supplement). As a result, we observed a profound decrease in the VEGF-A-stimulated proliferation rate in S100A6-silenced HUVECs compared with the control siRNA-treated group using 3 independent methods: (1) reduced cell numbers were assessed by nuclear DAPI staining ( Figure IIB in the online-only Data Supplement), whereas (2) diminished DNA synthesis was measured by nuclear incorporation of fluorescent EdU (5-ethynyl-2'-deoxyuridine) and (3) decreased anti-Ki67 immunofluorescence signal ( Figure 2B ). To further investigate migration as a crucial EC function in the setting of vascular injury repair, we used a wound-healing chemokinesis assay that showed a trend toward reduced migration of S100A6-depleted cells ( Figure  IIC in the online-only Data Supplement). In addition, an in vitro angiogenesis (Matrigel tube formation) assay, assessing both migration and proliferation capacity of ECs, was carried out and revealed an almost 50% reduction in tube formation capabilities of S100A6 knockdown ECs ( Figure IIC in the online-only Data Supplement). Taken together, these results indicated that S100A6 is indispensable for EC function, especially proliferation. In a next step, we combined time-resolved transcriptome data and bioinformatic analyses to decipher the molecular pathways transmitting the effect of S100A6 depletion in EC cell cycle regulation. Figure 1 . S100A6 is upregulated during the vascular remodeling process after endothelial cell injury and after growth factor stimulation in endothelial cells. A, Representative immunofluorescence (IF) stainings of S100A6 localization in porcine coronary arteries after percutaneous coronary intervention. Top, No stent implantation control, right coronary artery (RCA). Middle, Fifteen days post stent implantation, left anterior descending coronary artery (LAD). Bottom, Thirty days post stent implantation, LAD (×63 magnification; scale bar, 10 µm; green=S100A6, red=CD31, and blue=DAPI). B, Immunoblot showing elevated S100A6 expression in human umbilical vein endothelial cells (HUVECs) after vascular endothelial growth factor A (VEGF-A) stimulation for indicated time points (n=6 individual experiments, each performed in duplicate; *P<0.05 vs 0 h time point/no stimulation, Friedman test with subsequent Dunn correction for multiple comparisons). C, Representative IF stainings of upregulated S100A6 expression in HUVECs after 6, 12, and 24 h of VEGF-A stimulation (×20 magnification; scale bar, 40 µm; red=S100A6 and blue=nuclear DAPI).
A B C
Dynamic Functional Transcriptome Analysis Reveals Antiproliferative Signaling in S100A6-Depleted Human ECs
We used Illumina HT-12v4 human bead arrays to quantify the HUVEC transcriptome response in siRNA-mediated S100A6 knockdown and control samples over 24 hours after VEGF-A stimulation. A principal component analysis on the normalized and Entrez ID filtered expression time series revealed a quantitative rather than qualitative separation of S100A6 knockdown and control siRNA-treated HUVEC transcriptomes over time ( Figure 3A ). This is evident from the green and black trajectories, marking the knockdown and control samples in principal component analysis space.
Although similar in shape, there is a shift along the second principal component (PC2), which indicates the change in related subsets of genes yet at different regulatory strengths. Next, we assessed the functional relevance of gene expression over time and performed a Gene Set Enrichment Analysis (GSEA) using the human Gene Ontology (GO) gene sets. 21 The analysis showed a decelerated activation of cell cycle/ A B Figure 2 . siRNA-mediated S100A6 silencing results in decreased endothelial cell proliferation. A, Left, Immunoblot from control and S100A6 siRNA-treated human umbilical vein endothelial cell (HUVEC) lysates after a time course of vascular endothelial growth factor A (VEGF-A) stimulation for indicated time points, confirming successful S100A6 knockdown (n=6 individual experiments; *P<0.05 vs corresponding control siRNA-treated cells and #P<0.05 vs control siRNA-treated cells at 0 h, Friedman test with subsequent Dunn correction for multiple comparisons). Right, Immunofluorescence (IF) stainings of S100A6 in control siRNA and S100A6 siRNA-treated HUVECs pre stimulus (0 h) and after 24 h of VEGF-A stimulation (×20 magnification; scale bar, 40 µm; red=S100A6 and blue=nuclear DAPI). B, Left, S100A6 knockdown and control HUVECs were stimulated with VEGF-A for 24 h, and cell proliferation was measured as ( cell division gene pathways after VEGF-A stimulation as a result of S100A6 knockdown. Heatmaps in Figure 3B indicate an early upregulation of such pathways at 12 hours (marked by red box) in control samples, whereas delayed activation in S100A6 knockdown HUVECs is present only after 24 hours. In line with the quantitatively different cellular responses, regulation of several cyclins and cyclin-dependent kinases to VEGF-A stimulation was mitigated after S100A6 knockdown, reflecting delayed cell cycle entry ( Figure IIIA and IIIB in the online-only Data Supplement). To systematically evaluate the S100A6-dependent effect of VEGF-A stimulation on HUVECs, we performed a paired GSEA on the shared duplicate time points in knockdown versus control cells using the Consensus Pathway Database gene sets. 22 The analysis unveiled a strong and persistent upregulation of a group of STAT1-responsive interferon-inducible genes with tetratricopeptide repeats (IFI and IFIT) and transmembrane proteins (IFITM) on S100A6 depletion ( Figure 3C and 3D; Figure IIIC in the online-only Data Supplement). The finding is supported by the previously reported role of IFITM1 as an inhibitor of cell cycle entry and progression in malignant cells. 9 Therefore, we continued by focusing on IFITM1 as a putative key driver of the cellular phenotype observed.
IFITM1 Silencing Restores Proliferation
Capacity in S100A6 Knockdown ECs S100A6 depletion resulted in a constitutive upregulation of both the IFITM1 gene transcript and its respective protein ( Figure 4A and 4B), although the response dynamics to VEGF-A stimulation differed over time. The excessive (up to 25-fold) IFITM1 mRNA expression translates into a 1.8-to 2.5-fold IFITM1 protein expression in S100A6 knockdown ECs, suggesting that IFITM1 might be subject to post-translational modifications in line with previous studies, concluding that especially regulators of cell cycle-specific functions tend to have unstable protein. 23 IFITM proteins have been reported to be regulated by palmitoylation and ubiquitination, for example. 24, 25 This might explain our finding that the increase in IFITM1 protein both in control and S100A6 knockdown cells is partially overcome by short-term VEGF-A treatment. To test the effect of increased IFITM1 protein levels, we conducted a dual S100A6/IFITM1 siRNA-mediated knockdown in HUVECs. IFITM1 silencing partially rescued the diminished proliferation rate in S100A6 knockdown cells in response to VEGF-A as measured by nuclear DAPI staining and nuclear EdU incorporation ( Figure 4C ). IFITM1 knockout alone did not result in a significantly different EC proliferation rate from control cells at baseline (data not shown) and in the presence of VEGF-A stimulation ( Figure IVA in the online-only Data Supplement). Interestingly, in addition to the plasma membrane, IFITM1 was previously shown to be localized on the endoplasmic reticulum, the Golgi apparatus, and cytoplasmic vesicles, indicating the possibility to influence expression and activity of proteins, including cell cycle regulators. 9, 26 Analysis of the IFITM1 protein localization pattern in HUVECs ( Figure  IVC in the online-only Data Supplement) and carotid arteries at baseline or after injury ( Figure IVD in the online-only Data Supplement) shows a granulated pattern within the cell; likewise, pointing to an organelle and vesicular localization, in addition, we cannot exclude nuclear localization.
These results not only supported the significance of the predicted role of most differentially expressed genes for the cellular phenotype as mentioned above but also identified IFITM1 as the first relevant molecular component in the anti proliferative pathway downstream of negative S100A6 expression changes. The next step was to ascertain regulators within this signaling pathway.
S100A6 Depletion Causes Increased STAT1 Activation in ECs
ChIPseq data from the ENCODE project indicated STAT1 and STAT2 and nuclear factor of κ-light polypeptide gene enhancer in B cells (NFKB) and DNA polymerase epsilon catalytic subunit A (POL2/POLE) as regulators of the IFITM1 promoter ( Figure VA in the online-only Data Supplement). 27 Those results were in line with previously published experimental data. 10 . Of note, S100A6 knockdown was sufficient to persistently activate STAT1 throughout VEGF-A stimulation ( Figure 5B ). Interestingly, VEGF-A stimulation in control siRNA-treated cells did not significantly increase STAT1 protein expression or phosphorylation over time. For a more comprehensive in silico assessment of putatively regulated STAT1 target genes, we matched our transcriptome data with previously identified STAT1 target genes. 28 We found 301 of 1440 target genes to be significantly regulated (q<0.05) upon S100A6 knockdown in HUVECs ( Table I in Table showing the most regulated interferon-inducible genes and their significance level on S100A6 knockdown when compared with control siRNA-treated cells at time point 0 h of the transcriptome time series analysis (q value was calculated from a moderated t test with false discovery rate correction using the R limma package). CENP indicates centromere protein; EPH, ephrin; LSU, large subunit; NTR, neurotrophin receptor; and SSU, small subunit.
STAT1 Knockdown Prevents IFITM1 Upregulation and Restores Proliferation in S100A6-Depleted ECs
To assess whether increased STAT1 activity actually accounts for the antiproliferative cellular phenotype, we subjected HUVECs to dual S100A6/STAT1 siRNA-mediated gene silencing. In line with our in silico pathway analysis, STAT1 depletion suppressed downstream IFITM1 upregulation in S100A6 knockdown ECs at baseline and after VEGF-A stimulation ( Figure 5C ) and in turn restored the proliferation capacity. Figure 5C depicts representative cell culture and immunofluorescence EdU incorporation images. In line with previous findings, 29, 30 Ki67 protein upregulation in S100A6/STAT1 gene-silenced HUVECs surpassed the VEGF-A-mediated Ki67 increase in corresponding control groups ( Figure 5C ). STAT1 knockdown alone also lead to a relative decrease in IFITM1 expression. However, the increase in cell proliferation was relatively mild ( Figure VIA in the online-only Data Supplement). Interestingly, although STAT1 knockdown decreased IFITM1, it did not affect S100A6 protein expression ( Figure VIB in the online-only Data Supplement). IFITM1 on the other hand did not affect STAT1 expression ( Figure IVB in the online-only Data Supplement). These results confirmed STAT1 as an upstream activator of IFITM1 in S100A6-depleted ECs and validated the in silico pathway prediction.
S100A6 Regulates STAT1 Activity in ECs Through PIAS Modulation
To determine the mechanism by which S100A6 might affect STAT1 activity, we first analyzed the phosphorylation status of the nonreceptor tyrosine kinases JAK1 and JAK2 ( Figure  VIIB in the online-only Data Supplement). Unchanged JAK1/2 activation largely ruled out direct actions on the kinases or paracrine effects that might have resulted in STAT1 activation in S100A6-depleted HUVECs. Hypothesizing that S100A6 might operate independent of JAK1/2, we drew our A C B Figure 4 . Interferon-inducible transmembrane protein 1 (IFITM1) is among the most regulated genes after S100A6 knockdown and a key regulator of S100A6 cell signaling. A, Reverse transcription polymerase chain reaction analysis for IFITM1 from RNA samples used in the illumina beadarrays was carried out to confirm the results of the transcriptome time series analysis (error bars were drawn when replicates were available). B, Cell lysates from control and S100A6 siRNA-treated human umbilical vein endothelial cells (HUVECs) after a time course of vascular endothelial growth factor A (VEGF-A) stimulation were collected and immunoblotted for IFITM1 (n=6 individual; *P<0.05 vs corresponding control siRNA-treated cells, Friedman test with subsequent Dunn correction for multiple comparisons). C, Left, S100A6, S100A6/IFITM1 knockdown, and control HUVECs were stimulated with VEGF-A for 24 h, and EdU (5-ethynyl-2'-deoxyuridine) incorporation was measured as EdU-positive cells vs the total number of cells (ie, nuclear DAPI-stained cells; n=6 individual experiments; *P<0.05 vs corresponding control siRNA-treated cells and #P=0.062 vs S100A6 siRNA-treated cells with 24 h of VEGF-A stimulation, Friedman test for repeated measures, Wilcoxon signed-rank test with subsequent correction for individual time-point comparisons). Right, Representative immunofluorescence images of serum/growth factor starved and VEGF-A-stimulated control, S100A6, and S100A6/IFITM1 knockdown HUVECs after EdU detection (×20 magnification; scale bar, 40 µm; green=EdU and blue=nuclear DAPI).
attention to negative regulators of STAT1. We observed persistent downregulation of PIAS genes in S100A6-depleted ECs (Figure 6A) , which was significant for the concerted downregulation of all 4 PIAS isoforms (PIAS1-4, shown as PIAS gene set, Figure 6B ) over time. In line with gene expression, the protein level of the STAT1 inhibitor PIAS1 was diminished in S100A6-depleted ECs, both at baseline and after VEGF-A stimulation ( Figure 6C ). A trend toward increased total and phosphorylated STAT1 protein ( Figure  VIIIA Figure 5 . Elevated interferon-inducible transmembrane protein 1 (IFITM1) expression and antiproliferative phenotype in S100A6-depleted endothelial cells is caused by signal transducers and activators of transcription 1 (STAT1) activation. A, Reverse transcription polymerase chain reaction analysis for STAT1 from RNA samples used in the gene array was carried out to confirm the results of the transcriptome time series analysis (error bars were drawn when replicates were available). B, Cell lysates from control and S100A6 siRNA-treated human umbilical vein endothelial cells (HUVECs) after a time course of vascular endothelial growth factor A (VEGF-A) stimulation were collected and immunoblotted for STAT1 and Tyr-701-phosphorylated STAT1 (n=6 individual experiments; *P<0.05 vs corresponding control siRNAtreated cells, Friedman test and subsequent Dunn correction for multiple comparisons). C, Left, Cell lysates from S100A6, S100A6/ STAT1 knockdown, and control HUVECs were collected after over night starvation and after VEGF-A stimulation and were immunoblotted for Ki67 (n=6 individual experiments) and IFITM1 (n=4 individual experiments for 0 h time point and n=6 individual experiments for 24 h time point; #P<0.05 vs corresponding control siRNA-treated cells, *P≤0.05 vs S100A6 siRNA-treated cells at 24 h, Friedman-Dunn test). Right, Representative cell culture images from S100A6, S100A6/STAT1 knockdown, and control HUVECs 24 h after VEGF-A stimulation (×4 magnification) and representative IF images from the corresponding experiment's EdU More reports emerged, suggesting that the STAT1 signaling pathway, including negative regulators, such as PIAS, might be targeted by micro-RNAs (miRNAs) via post-transcriptional regulation. 31, 32 Concordantly, applying miRNA-mRNA interaction prediction, our serial transcriptome analysis unveiled that certain miRNAs, for example, miR548c, negatively correlate with the expression of PIAS genes ( Figure 6E ; Figure  VIIIB in the online-only Data Supplement).
We also considered additional mechanisms of putative S100A6 and STAT1 interactions. Tyrosine phosphatases constitute a second class of negative regulators of STAT. Previous studies indicated that cytoplasmic tyrosine phosphatases SH2containing phosphatase 1 and 2 (SHP-1 and SHP-2, genes PTPN6 and PTPN11) and protein tyrosine phosphatase 1B (PTP1B, gene PTPN1) are involved in dephosphorylating activated STAT1. 33 However, none of the genes encoding for above proteins were differentially expressed in S100A6-depleted HUVECs ( Figure VIIC in the online-only Data Supplement). A third type of repressor, SOCS, represents a negative feedback loop evoked by nuclear STAT. 16 SOCS proteins bind to phosphorylated nonreceptor tyrosine kinases interrupting the transmission between JAK and STAT molecules. Interestingly, the SOCS 1 to 3 gene set was transiently downregulated in S100A6 knockdown HUVECs ( Figure VIID in the onlineonly Data Supplement). However, SOCS proteins function in part through ubiquitin-dependent degradation and inhibition of the autocatalytic domain of JAK1/2. 11, 16 Unchanged protein levels and phosphorylation of the latter therefore argued against a meaningful role of diminished SOCS expression in S100A6-depleted ECs ( Figure VIIB in the online-only Data Supplement). In summary, these data suggest that S100A6 is necessary to prevent induction and activation of STAT1 in ECs most likely via PIAS.
S100A6 Is Not Sufficient to Alter Endothelial STAT1 Signaling
We further sought to understand whether S100A6 was sufficient to alter STAT1 signaling in ECs. We applied an adenoviral gene transfer approach to overexpress S100A6 in HUVECs ( Figure 7A ). S100A6 overexpression neither changed STAT1 nor IFITM1 or PIAS1 expression, indicating that S100A6 is necessary for endothelial proliferation by controlling STAT1 signaling but not sufficient to downmodulate the pathway.
VEGF-A-Mediated Proproliferative Signaling in ECs Is Not Disrupted by S100A6 Knockdown
We finally determined whether reduced HUVEC S100A6 would interfere with VEGF-A-induced cell cycle entry and progression. Interestingly, PI3K-AKT-MAPK signaling pathways remained unchanged at the transcriptional level according to GSEA ( Figure IXA in the online-only Data Supplement). In line with this result, neither phosphorylation nor protein abundance of AKT and extracellular signal regulated kinase 1/2 (ERK1/2) was altered in S100A6-depleted HUVECs (Figure IXB and IXC in the online-only Data Supplement). Of note, a trend toward a premature ERK1/2 deactivation was observed after 24 hours of VEGF-A stimulation in S100A6depleted cells and is therefore rather a possible late downstream effector of the pathway than a cause for the reduced proliferation observed in S100A6-depleted HUVECs. These data suggest that the antiproliferative effect of STAT1 activation in S100A6 knockdown cells is independent of AKT or MAPK signaling.
Discussion
Previous studies demonstrated a role for S100A6 in the regulation of cell cycle entry and progression of HUVECs. 3 S100A6 gene silencing caused significant accumulation of HUVECs in G1/S and G2/M phase transition and cell cycle arrest. Similar phenotypes were observed both in fibroblasts and cancerous cells. 19, 34, 35 The underlying molecular pathways, however, by which S100A6 might affect EC proliferation remained elusive.
On the basis of experimental data supporting a role for S100A6 in efficient reendothelialization of injured arteries, this is the first report that causatively links S100A6 to the attenuation of antiproliferative STAT1 signaling in ECs. Discovery of this unexpected molecular liaison was guided by the time-resolved transcriptional STAT1-dependent fingerprint in S100A6 gene-silenced HUVECs. The unbiased origin subsequently fueled bioinformatic analysis of the putative molecular pathway, which in turn guided in vitro experimental validation of predicted key factors. Given S100A6's widespread expression in mammalian cells, it is tempting to speculate that the biological effect of the S100A6/STAT1 signaling axis might not be limited to EC and vascular molecular medicine. S100A6 might act as a general attenuator of STAT1 signaling with potential relevance to various fields in molecular medicine, but that requires further investigation.
Focusing on the most differentially regulated genes that are expected to shape the antiproliferative phenotype, our time-resolved transcriptome analysis first identified IFITM1 as a downstream molecular effector, also owing to its previously described role as a cell cycle inhibitor amid other candidates. 9 Of note, S100A6 gene silencing was sufficient to upregulate IFITM1 and other IFI proteins before and throughout VEGF-A stimulation.
The key role of IFITM1 was validated by partially restoring the proliferative capacity in VEGF-A-stimulated S100A6depleted HUVECs when IFITM1 protein was diminished. This result is in line with a previous report showing that IFITM1 stabilizes p53 in cancer cells by directly inhibiting Thr55 phosphorylation. Enhanced p53 translational activity consecutively induced the cyclin-dependent kinase inhibitor 1 (p21). 9 Subsequent GSEA analysis in S100A6-depleted HUVECs confirmed concordant transcriptional changes in various cell cycle pathways over time, such as cell division or G1/S. IFITM1's increased abundance might therefore present a molecular barrier for EC cycle entry rather than being an irrevocable blockade.
In support of this argument, we observed an expression delay across numerous relevant cyclins, such as E1, L2, Y, and D2, as well as various cyclin-dependent kinase genes in S100A6-silenced HUVECs. This pattern and the fact that IFITM1 knockdown was not sufficient to fully restore the proliferative capacity in S100A6-depleted HUVECs or independently drive EC proliferation argue against the notion that the antiproliferative effect can solely be pinpointed to an IFITM1/ p53-dependent mechanism. Other inhibitory mechanisms might synergize and impede cell cycle entry and progression at multiple levels.
Leveraging previously published CHIPseq data on STAT1-responsive elements within the IFITM1 promoter, bioinformatic analysis predicted upstream STAT1 activation as the most likely transcriptional effector for the antiproliferative transcriptional signature in S100A6-depleted HUVECs. Our experimental data strongly supported this argument because STAT1 signaling was significantly enhanced in S100A6 knockdown HUVECs, and STAT1 depletion rescued the expression of the pan-cell cycle marker Ki67 protein and the cell proliferation rate in response to VEGF-A stimulation. Of note, STAT1 depletion in S100A6 knockdown cells that prevented IFITM1 upregulation resulted in greater restoration of proliferative capacity than IFITM1 siRNA-mediated inhibition alone. This suggests again that STAT1 signaling governs a multifactorial set of downstream cell cycle inhibitors in this setting, for example, other interferon-inducible proteins highly regulated after S100A6 depletion.
The JAK-STAT signaling pathway usually transmits information from a variety of ligands, including cytokines, hormones, and growth factors and their receptors to gene promoters on DNA in the cell nucleus and thereby modulates cellular activities. 36 Stimulation of the receptor results A B Figure 7 . Novel signaling module linking S100A6 to control of signal transducers and activators of transcription 1 (STAT1) signaling. A, Cell lysates from S100A6 adenovirus (FLAG tagged) and control GFP adenovirus-infected human umbilical vein endothelial cells (HUVECs; 48 h) were collected and immunoblotted for interferon-inducible transmembrane protein 1 (IFITM1), protein inhibitor of activated STAT 1 (PIAS1), STAT1, S100A6, and FLAG (n=3 individual experiments, not significant). B, The schematic highlights the molecular control of antiproliferative STAT1 signaling in endothelial cells (ECs) via S100A6. Our findings indicate that S100A6 might constitutively facilitate the activity of the STAT1 suppressor PIAS (1) . Loss of S100A6 expression subsequently entails STAT1 activation via loss of PIAS activity independent of Janus kinases 1 and 2 (JAK1/2), SH2-containing phosphatase (SHP), and suppressors of cytokine signaling (SOCS) signaling (2) . STAT1 in turn activates a set of antiproliferative genes, including IFITM1 besides others (3) that oppose cell cycle entry in part most likely via previously described p53/p21 activation. Of note, vascular endothelial growth factor A (VEGF-A)-mediated proliferative signaling pathways, such as extracellular signal-regulated kinase (ERK1/2) and AKT, are not affected by antiproliferative STAT1 signaling, indicating downstream competitive integration of pro-and antiproliferative signals for cell cycle decision entry. Colored elements highlight in silico predicted and experimentally validated components of the novel S100A6/STAT1/IFITM1 signaling module. Grey elements are not affected by S100A6 signaling as predicted by in silico modeling and experimental validation. In summary, S100A6 might be indispensable for timely cell cycle entry by attenuating antiproliferative STAT1 signaling.
in JAK activation, which in turn leads to STAT phosphorylation, dimerization, and subsequent translocation into the nucleus. 11, 36 It is a major signaling alternative to classical second messenger systems. Our data however indicate that STAT1 signaling because of diminished S100A6 protein levels in ECs depends neither on receptor stimulation nor on JAK1/2 activation.
We therefore focused on molecular mechanisms that might result in STAT1 disinhibition. Among those factors known to restrict STAT1 activity, PIAS genes emanated from our transcriptome time series data and consecutive in silico analysis as most likely candidates. PIAS1 protein was actually found to be decreased in S100A6-depleted HUVECs before VEGF-A stimulation, and this suppression endured over time. Previous studies showed that PIAS1 apparently exerts a high degree of specificity toward STAT1 inhibition. 13 PIAS1-depleted ECs exhibited a tendency for attenuated proliferation and STAT1 upregulation with increased STAT1 activity. One explanation for the rather mild phenotype of PIAS1-depleted HUVECs is that S100A6 might regulate a more complex signaling module. For example, our data indicate that PIAS2-4 will most likely add to the effect in this setting. Another reason is that STAT1 expression and activity are not significantly increased in VEGF-A-stimulated HUVECs. In agreement with this observation, we also see a mild effect of STAT1 silencing for VEGF-A-stimulated HUVEC proliferation, as opposed to the significant effect that STAT1 silencing has in S100A6depleted cells, after interferon γ treatment or in vivo. 30 These results are in line with previous studies showing that PIAS1 overexpression inhibits STAT1-mediated gene expression and VEGF-induced proliferation after interferon γ treatment. 13, 30 However, it has also been reported that PIAS1 induction resulted in reduced expression of p21, and thereby, enhanced proliferation, and PIAS1 silencing lead to growth arrest in human osteosarcoma cells. 37 Further experimentation is needed to decipher the role of other PIAS proteins in S100A6depended STAT1 regulation and the functional consequence of PIAS1 overexpression in S100A6-depleted HUVECs.
Several inhibitory mechanisms of PIAS have been described. For example, PIAS1 has been shown to negatively interfere with the DNA-binding activity of STAT1, thereby acting as an inhibitory transcriptional coregulator. 13 Furthermore, SUMOylation (SUMO: small ubiquitin-like modifier) by PIAS makes tyrosine-phosphorylated STAT1 more susceptible to inactivation by nuclear phosphatases (eg, TC45). 15 Both mechanisms could be an explanation for the prolonged STAT1 expression and activity, as well as the upregulation of STAT1 target genes in S100A6 knockdown HUVECs. However, because S100A6 knockdown as the single stimulus increased STAT1 activity ( Figure VIIA in the online-only Data Supplement), it seems likely that an additional PIAS-STAT1 inhibitory mechanism is directly influenced by S100A6 in the cytoplasm. Droescher et al 14 have shown that SUMOylation of STAT1 precludes phosphorylation of the Tyr-701 residue. Their data also suggest that SUMO interferes in the very moment that STAT1 is phosphorylated at the receptor level (ie, by the receptor tyrosine kinase itself or the nonreceptor tyrosine kinases). This mechanism seems to suggest that SUMOylation, for example by PIAS1, is a way the cell maintains active STAT1 homeostasis required to balance pro-and antiproliferative signaling. However, we cannot exclude that additional (yet unknown) mechanisms have an effect on STAT1 in S100A6 knockdown ECs.
Nevertheless, PIAS downregulation in S100A6-depleted HUVECs seems as an evident mechanism to facilitate STAT1 disinhibition. It explains why S100A6 knockdown does not interfere with the proproliferative signaling pathway and does not hamper receptor or JAK activity. Importantly, PIAS proteins can also negatively interfere with NFKB signaling. 38 Unchanged NFKB expression and activation levels nevertheless support the notion that altered PIAS activity in S100A6 knockdown HUVECs might indeed be limited to STAT1 activation. It has previously been described that PIAS might be regulated by miRNAs. 31, 32, 39 Our serial transcriptome analysis unveiled that certain miRNAs, for example, miR548c, negatively correlate with the expression of PIAS1 and PIAS3. However, a mechanistic interaction of miRNAs and PIAS genes would require further validation.
Although SOCS genes, which constitute an inducible feedback mechanism for the JAK1/2-STAT1 pathway, were also moderately expressed over time, unchanged JAK1/2 protein levels and phosphorylation largely ruled out a relevant role for enhanced STAT1 activity. S100A6 knockdown nonetheless seems to interrupt the feedback mechanism because elevated STAT1 activity would have been expected to result in increased SOCS protein levels in our experimental setting. 16, 17 Unchanged STAT1 signaling after S100A6 overexpression and intact VEGF-A-mediated proliferative signaling through ERK1/2 and AKT eventually corroborated the notion that S100A6 protein may act as an independent molecular brake that facilitates cell cycle entry by preventing simultaneous antiproliferative STAT1 signaling. Upregulation of S100A6 by VEGF-A in HUVECs is in line with this notion. Previous findings by Bao et al 3 showing that forced S100A6 expression has no to at best minimal effects on EC proliferation further substantiate our results. Our findings of a premature ERK1/2 deactivation after 24 hours of VEGF-A stimulation in S100A6-depleted cells could underline this possible mechanism of how IFITM1 regulates its downstream effectors.
Overall, our study sheds new light onto S100A6's role as a cell cycle regulator in ECs through discovery of a hitherto unknown link to STAT1 signaling ( Figure 7B ). Our in vivo results indicate a relevant role for S100A6 and STAT1 signaling in efficient reendothelialization after intimal injury. Interestingly, Fludarabine, a pharmacological STAT1 inhibitor, was therapeutically tested in a rat carotid artery balloon injury model before and resulted in reduced neointimal hyperplasia through inhibition of SMC proliferation. 40 Multiple studies have confirmed that STAT1 is directly stimulated by angiotensin II in SMCs and responsible for angiotensininduced proliferation of this cell type. We could confirm that STAT1 ( Figure VIC in the online-only Data Supplement) and its downstream effector IFITM1 ( Figure IVD in the onlineonly Data Supplement) were expressed in neointima-forming SMCs during the vascular remodeling process after balloon injury of carotid arteries. Because of the disrupted vascular architecture after injury that complicates EC discrimination, further research is warranted to clarify lineage specific roles of S100A6. Nevertheless, because the data presented in this study, and previous reports investigating angiogenesis in STAT1 −/− mice, 30 suggest that, contrary to SMCs, STAT1 inhibits proliferation in ECs, it seems that STAT1 resumes opposing functions, alike angiotensin II itself, depending on the stimulus and cell lineage. Therefore, Fludarabine's inhibition of STAT1 could exert double-positive effects as a therapeutic agent to prevent excessive neointima formation after vascular injury because of inhibited SMC proliferation and unhindered EC proliferation. However, given Fludarabine's ability to inhibit DNA synthesis and cytotoxic effects in ECs (data not shown), 41 the positive effects of STAT1 inhibition unlikely unfold in ECs. Therefore, characterization of upstream and downstream effectors, such as S100A6 and IFITM1, might stimulate novel therapeutic strategies.
Discovery of the unexpected molecular link between S100A6 and STAT1 became possible by combining transcriptome time series analysis with bioinformatic pathway modeling and subsequent experimental validation. Further in vivo studies are warranted to test the therapeutic impact of the candidates that emerged from this study, such as IFITM1 or S100A6, to facilitate healing of the arterial intimal layer. Likewise, additional studies are necessary to decipher the role of S100A6 for SMC proliferation. Manipulating vascular S100A6 expression might bear the risk of being a doubleedged sword and cell type-specific formulations might be necessary to safely exploit its inherent therapeutic potential. Originating from an unbiased approach, our strategy nevertheless has the potential for a comprehensive characterization of novel signaling pathways with relevance for molecular medicine.
